Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. MRK
8. LVS
9. CSX
10. LRCX

Go back to Moderna (MRNA) Reports Interim Data From Phase 1 Study of mRNA-2752 Triplet Program

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting

November 12, 2021 5:23 PM EST

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced interim data from an ongoing Phase 1 clinical study of mRNA-2752 (Triplet) in patients with accessible solid tumors and lymphomas. The data showed that the Companys mRNA Triplet program given in combination with AstraZenecas durvalumab (IMFINZI®) was tolerated at all dose levels tested and elicited evidence of anti-tumor activity. The recommended dose for expansion (RDE) is up to of 8mg mRNA-2752 + durvalumab.

We are encouraged by the interim data from our... More